Description
Badges/Icons (below price):
- Purity Verified (HPLC/LC-MS)
- Batch COA Available (QR on vial & page)
- Secure Payments (EMT + Card + Crypto)
- Fast Canada Shipping
Science & Mechanism (accordion section)
How It Works:
Semaglutide is a GLP-1 receptor agonist that slows gastric emptying, enhances insulin secretion, suppresses glucagon, and modulates appetite signals — leading to reduced caloric intake and weight loss.
Clinical Evidence:
In the STEP-1 Phase III trial, 2.4 mg weekly produced a mean weight reduction of ~14.9% vs. ~2.4% in placebo, sustained at 68 weeks. Higher-dose trials (7.2 mg weekly) demonstrated ~20.7% loss, with 33.2% achieving ≥25% loss, per Novo Nordisk 2025 data.
💧 Reconstitution & Dosing Tables (Weight Loss Peptides)
Semaglutide (10 mg vial + 2 mL BAC water)
-
Final concentration = 5 mg/mL → 50 mcg per unit (0.01 mL) on an insulin syringe.
Dose |
Volume (mL) |
Syringe Units |
0.25 mg |
0.05 mL |
5 units |
0.5 mg |
0.10 mL |
10 units |
1.0 mg |
0.20 mL |
20 units |
1.7 mg |
0.34 mL |
34 units |
2.4 mg |
0.48 mL |
48 units |
Dosing Guide (educational)
Titration Schedule (Weekly SubQ):
| Phase | Dose (mg) | Recommended Duration |
| Initiation | 0.25 mg | Weeks 1–4 |
| Escalation | 0.5 mg | Weeks 5–8 |
| Escalation | 1.0 mg | Weeks 9–12 |
| Escalation | 1.7 mg | Weeks 13–16 |
| Maintenance | 2.4 mg | Week 17 onward |
If tolerability is an issue, maintain a lower dose a week longer before escalating.
Missed Dose Guidance:
Administer within 5 days of the missed dose; if not possible, skip and resume regular schedule. Maintain ≥48 hours spacing between doses.
Vial Reconstitution (Sample Protocol)
Assuming 10 mg per vial, reconstitute with 2 mL bacteriostatic water → 1 mg per 0.2 mL syringe volume.
Example:
- 0.25 mg → 0.05 mL (5 units on insulin syringe)
- 2.4 mg → 0.48 mL (48 units on syringe)
Storage & Handling
- Freeze-dry (lyophilized) product must be refrigerated (2–8 °C).
- After reconstitution, store at 4 °C for up to 30 days or −20 °C for longer stability; protect from light.
Disclaimers & Legal Copy
- Content is educational, not personalized medical advice.
- Semaglutide is not FDA/Health Canada approved for cosmetic or optimization use.
- Consult a qualified professional before use.
FAQ Section (toggle list)
- What’s a typical duration of use?
Many users continue at maintenance dose for 6–12 months or longer, depending on goals. - Is it safe to combine with other peptides?
Combining with energy/metabolic peptides like MOTS-c is common—but start one at a time to monitor tolerance. - How do I read the COA?
COA shows >99% purity via HPLC and confirmation by MS. Available via QR code on the vial.
Quick Referential Summary Block
| Item | Details |
| Mechanism | GLP-1RA (slows digestion, reduces appetite) |
| Peak Human Weight Loss | ~15% at 68 weeks (2.4 mg) |
| Dosing Titration | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly |
| Safety Tolerance | Escalate only if tolerated |
| Testing | Batch COA linked (HPLC + MS) |
📚 Semaglutide — References & Product Page Citations
🔗 Direct References (Medical Papers & Sources)
- NEJM STEP-1 Trial (RCT, 2.4 mg dose) – 14.9% weight loss
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 - PubMed Abstract (STEP-1 Data)
https://pubmed.ncbi.nlm.nih.gov/33567185/ - NEJM Commentary on STEP-1
https://www.nejm.org/doi/full/10.1056/NEJMe2101705 - Nature Medicine – Long-term BMI outcomes at 104 weeks
https://www.nature.com/articles/s41591-024-02996-7 - Nature Medicine – Two-year effects (STEP-5 Trial)
https://www.nature.com/articles/s41591-022-02026-4 - PMC Cohort Study – Real-world outcomes (3 & 6 months)
https://pmc.ncbi.nlm.nih.gov/articles/PMC9486455/ - PMC Meta-Analysis of STEP Trials
https://pmc.ncbi.nlm.nih.gov/articles/PMC10092086/ - Wikipedia Overview (general, approvals, safety)
https://en.wikipedia.org/wiki/Semaglutide
✅ Suggested Product Page Citations
- Mean weight loss of 14.9% at 68 weeks with 2.4 mg weekly dosing (STEP-1 trial). NEJM, PubMed
- Sustained reductions after 2 years (STEP-5): ~15.2% mean weight loss. Nature Medicine
- BMI improvements at 104 weeks: 52.4% of participants moved into a lower BMI category. Nature Medicine
- Real-world evidence: ~5.9% loss at 3 months, ~10.9% at 6 months. PMC
- Meta-analysis: Confirms consistent 14.9–17.4% weight loss across STEP trials. PMC





Reviews
There are no reviews yet.